BROWNSTEIN HYATT FARBER SCHRECK, LLP for NOVARTIS
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 20, 2020 | $50,000 | Replaced |
| 1st Quarter - Amendment (this page) | Jul 8, 2020 | $50,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases H.R. 748 CARES Act, Issues related to COVID-19 treatment
| Lobbyist | Covered position, as disclosed |
|---|---|
| NADEAM ELSHAMI | — |
| MARC LAMPKIN | — |
| BRIAN MCKEON | — |
| RADHA MOHAN | — |
| JEROME MURRAY | — |
| ZACHARY PFISTER | — |
| BRIAN WILD | — |
Medical/Disease Research/Clinical Labs MED
Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases H.R. 748 CARES Act, Issues related to COVID-19 treatment
| Lobbyist | Covered position, as disclosed |
|---|---|
| EMILY FELDER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.